Addex Therapeutics Ltd (ADXN) - Total Liabilities
Based on the latest financial reports, Addex Therapeutics Ltd (ADXN) has total liabilities worth $1.60 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Addex Therapeutics Ltd net asset momentum to track the company's year-over-year net asset growth rate.
Addex Therapeutics Ltd - Total Liabilities Trend (2006–2025)
This chart illustrates how Addex Therapeutics Ltd's total liabilities have evolved over time, based on quarterly financial data. See cash generation quality of Addex Therapeutics Ltd to measure how efficiently the company converts operating cash flow to free cash.
Addex Therapeutics Ltd Competitors by Total Liabilities
The table below lists competitors of Addex Therapeutics Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Qlife Holding AB
ST:QLIFE
|
Sweden | Skr12.89 Million |
|
Green Technology Metals Ltd
AU:GT1
|
Australia | AU$7.41 Million |
|
Spectrumone publ AB
ST:SPEONE
|
Sweden | Skr40.81 Million |
|
Longvie SA
BA:LONG
|
Argentina | AR$16.05 Billion |
|
Gungnir Resources Inc
V:GUG
|
Canada | CA$29.60K |
|
Battery Age Minerals Ltd
AU:BM8
|
Australia | AU$2.63 Million |
|
cbdMD Inc
NYSE MKT:YCBD
|
USA | $3.78 Million |
|
WH Smith PLC
LSE:SMWH
|
UK | GBX1.29 Billion |
Liability Composition Analysis (2006–2025)
This chart breaks down Addex Therapeutics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Addex Therapeutics Ltd stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.34 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.25 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Addex Therapeutics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Addex Therapeutics Ltd (2006–2025)
The table below shows the annual total liabilities of Addex Therapeutics Ltd from 2006 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.60 Million | +59.77% |
| 2024-12-31 | $1.00 Million | -71.37% |
| 2023-12-31 | $3.50 Million | +3.78% |
| 2022-12-31 | $3.37 Million | -39.95% |
| 2021-12-31 | $5.61 Million | +0.69% |
| 2020-12-31 | $5.57 Million | -25.76% |
| 2019-12-31 | $7.50 Million | +152.42% |
| 2018-12-31 | $2.97 Million | +72.79% |
| 2017-12-31 | $1.72 Million | +17.50% |
| 2016-12-31 | $1.46 Million | +19.49% |
| 2015-12-31 | $1.23 Million | -25.89% |
| 2014-12-31 | $1.65 Million | -42.06% |
| 2013-12-31 | $2.85 Million | -47.59% |
| 2012-12-31 | $5.44 Million | -44.33% |
| 2011-12-31 | $9.78 Million | -0.91% |
| 2010-12-31 | $9.87 Million | -10.05% |
| 2009-12-31 | $10.97 Million | -17.73% |
| 2008-12-31 | $13.34 Million | +43.92% |
| 2007-12-31 | $9.27 Million | +127.45% |
| 2006-12-31 | $4.07 Million | -- |
About Addex Therapeutics Ltd
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for neurological disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant, which is in phase 1 clinical trial for the treatment of post-stroke/TBI recovery, as well as to treat Parkinson's disease levodopa-in… Read more